Orphan drug designation provides key incentives of the ODA, including significant tax credits for qualified clinical testing. The BBCR team will empower sponsors with medical insight, ODA application experience, strategic clinical plan, and streamlined trials design.
– Boston Biotech Clinical Research (BBCR). Strategic Clinical Innovation Experts. Rare Disease, Clinical Trials, Clinical Research, & Biologics. We work with biotech, pharmaceutical, and device companies to develop clinical/regulatory road-maps consisting with simplified clinical programs, streamlined protocols, and cost-effective clinical trials. Our experienced team provides innovative strategies that meet your goals.
Developing drugs with substantial benefits in smaller, molecularly defined, pharmacologically relevant subpopulations of patients with the same clinically recognized disease is increasingly being viewed as a viable pathway for bringing drugs to market.
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.
Tags: 
